Bilenker Joshua H. 4

What Happened Joshua H. Bilenker, a director of Sana Biotechnology, Inc. (SANA), received a grant of derivative securities covering 90,000 shares on June 4, 2026. The Form 4 reports the transaction as an award/acquisition (code A) with a reported price of $0.00 (i.e., a grant of an option/award rather than a market purchase). No cash value or exercise price is provided in the information summarized here.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely filing).
• Transaction type: Grant of derivative securities (code A) — 90,000 shares; reported price $0.00.
• Vesting/exercise: Footnote F1 — the option vests and becomes exercisable 100% on the earlier of (i) June 4, 2027 or (ii) immediately prior to the 2027 annual meeting of stockholders, provided continuous service through that date.
• Shares owned after transaction: Not specified in the provided report.
• Exhibit noted: Ex. 24 — Power of Attorney.

Context This is a derivative award (an option-type grant) that does not represent immediate share ownership or a market purchase/sale. The award vests in full on a specified future date contingent on continued service; there is no indication the shares were exercised or sold. Such grants are common for board compensation and do not by themselves signal an immediate trading view.